Activated Carbon nanoparticles Loaded with Metformin for Effective Against Hepatocellular Cancer Stem Cells

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan. Int J Cancer. 2000;94(2):153–156. doi:10.1002/ijc.1440
   Web of Science ®Google Scholar
• Hollstein MC, Wild CP, Bleicher F, et al. p53 mutations and aflatoxin B 1 exposure in hepatocellular carcinoma patients from Thailand. Int J Cancer. 1993;53:51–55. doi:10.1002/ijc.2910530111
   PubMed Web of Science ®Google Scholar
• Tong CM, Ma S, Guan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol. 2011;26:1229–1237. doi:10.1111/j.1440-1746.2011.06762.x
   PubMed Web of Science ®Google Scholar
• Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003;22:5093–5107. doi:10.1038/sj.onc.1206557
   PubMed Web of Science ®Google Scholar
• Song Y-J, Zhang S-S, Guo X-L, et al. Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 2013;339:70–81. doi:10.1016/j.canlet.2013.07.021
   PubMed Web of Science ®Google Scholar
• Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252–261. doi:10.1016/j.cgh.2006.01.001
   PubMed Web of Science ®Google Scholar
• Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol. 2010;53:568–577. doi:10.1016/j.jhep.2010.05.003
   PubMed Web of Science ®Google Scholar
• Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol. 2008;26:2795–2799. doi:10.1200/JCO.2008.17.7436
   PubMed Web of Science ®Google Scholar
• Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322:1–7. doi:10.1016/j.canlet.2012.02.002
   PubMed Web of Science ®Google Scholar
• Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675–699. doi:10.1146/annurev.cellbio.22.010305.104154
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008;27:1749–1758. doi:10.1038/sj.onc.1210811
   PubMed Web of Science ®Google Scholar
• Ma S, Chan KW, Hu L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542–2556. doi:10.1053/j.gastro.2007.04.025
   PubMed Web of Science ®Google Scholar
• Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820–824. doi:10.1016/j.bbrc.2006.10.128
   PubMed Web of Science ®Google Scholar
• Stephanie M. Biology and clinical implications of CD133+liver cancer stem cells. Exp Cell Res. 2013;319:126–132. doi:10.1016/j.yexcr.2012.09.007
   PubMed Web of Science ®Google Scholar
• Dowling R, Goodwin P, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33. doi:10.1186/1741-7015-9-33
   PubMed Web of Science ®Google Scholar
• Yang Q, Zhang T, Wang C, Jiao J, Li J, Deng Y. Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+cancer stem-like cells. Eur J Pharma Biopharmaceut. 2014;88:737–745. doi:10.1016/j.ejpb.2014.10.006
   PubMed Web of Science ®Google Scholar
• Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37:207–218. doi:10.1016/j.canep.2012.12.009
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009;69:7507–7511. doi:10.1158/0008-5472.CAN-09-2994
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Barco SD, et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Menendez Breast Cancer Res Treat. 2011;126:355–364. doi:10.1007/s10549-010-0924-x
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cu Fi S, Del Barco S, Martin-Ca Stillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial–mesenchymal transition (EMT) status. Cell Cycle. 2010;9:3807–3814. doi:10.4161/cc.9.18.13131
   PubMed Web of Science ®Google Scholar
• Bao B, Wang Z, Ali S, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012;5:355–364. doi:10.1158/1940-6207.CAPR-11-0299
   PubMed Web of Science ®Google Scholar
• Qiu-Lian Q, Ying-Ge Z. Effects of activated carbon nanoparticles on human gastric carcinoma cell line BGC-823 in vitro. Military Med Sci. 2009;33(1):29–32.
   Google Scholar
• Peng F. The Mode of Cross-Membrane Transferring and Biological Effects of Nanoparticles Doctoral dissertation. Zhengzhou University; 2011:27–36.
   Google Scholar
• Sun L, Cai Y, Liu Y, Song D, Liu, Y, Yao H, Zhang Y. Activated carbon nanoparticles as carriers of anticancer drugs. Nano Biomed Eng. 2013;5(2):94–101.
   Google Scholar
• Yang Z, Zhao JX, Li PF, Zhang YG. Effects of activated carbon nanoparticles on anti cancer effect of 5-Fu. Bull Acad Mil Med Sci. 2009;33(5):416–420.
   Google Scholar
• Zhang H, Sun L, Zhang YG. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles using bioluminescence imaging technology. Mil Med Sci. 2011;35(4):299–302.
   Google Scholar
• Qu QL, Zhang YG, Yang LZ, Sun L. Intraperitoneal chemotherapy with mitomycin C bound to activated carbon nanoparticles for nude mice bearing human gastric carcinoma. Zhonghua Zhong Liu Za Zhi. 2006;28(4):257–260. Chinese.
   PubMedGoogle Scholar
• Zhong Y, Shuzheng M, Yingge Z. Using activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agents. J Nanosci Nanotechnol. 2010;10(12):8603–8609.
   PubMed Web of Science ®Google Scholar
• Jiang S, Wang X, Zhang Z, et al. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells. Int J Nanomedicine. 2016;(11):5505–5518. doi:10.2147/IJN.S115428
   PubMedGoogle Scholar
• Jumelle C, Mauclair C, Houzet J, et al. Delivery of macromolecules into the endothelium of whole ex vivo human cornea by femtosecond laser-activated carbon nanoparticles. Br J Ophthalmol. 2016;100(8):1151–1156. doi:10.1136/bjophthalmol-2015-307610
   PubMed Web of Science ®Google Scholar
• Xie J, Yong Y, Dong X, et al. Therapeutic nanoparticles based on curcumin and bamboo charcoal nanoparticles for chemo-photothermal synergistic treatment of cancer and radioprotection of normal cells. ACS Appl Mater Interfaces. 2017;9(16):14281–14291. doi:10.1021/acsami.7b02622
   PubMed Web of Science ®Google Scholar
• Yao HJ, Sun L, Liu Y, et al. Monodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cells. Carbon. 2016;96:362–376. doi:10.1016/j.carbon.2015.09.037
   Web of Science ®Google Scholar
• Yao H, Sun L, Li J, et al. A novel therapeutic siRNA nanoparticle designed for dual-targeting CD44 and Gli1 of gastric cancer stem cells. Int J Nanomedicine. 2020;15:7013–7034. doi:10.2147/IJN.S260163
   PubMed Web of Science ®Google Scholar
• Chen H, Luo Z, Dong L, et al. CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS One. 2013;8:e56878. doi:10.1371/journal.pone.0056878
   PubMed Web of Science ®Google Scholar
• Dontu G, Abdallah WM, Foley JM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17:1253–1270. doi:10.1101/gad.1061803
   PubMed Web of Science ®Google Scholar
• Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res. 2004;6:605–615. doi:10.1186/bcr920
   PubMed Web of Science ®Google Scholar
• Eyre R, Alférez DG, Spence K, et al. Patient-derived mammosphere and xenograft tumour initiation correlates with progression to metastasis. J Mammary Gland Biol Neoplasia. 2016;21(3–4):99–109. doi:10.1007/s10911-016-9361-8
   PubMed Web of Science ®Google Scholar
• Mariya S, Dewi FN, Suparto IH, et al. Mammosphere culture of mammary cells from cynomolgus macaques (Macaca fascicularis). Comp Med. 2019;69(2):144–150. doi:10.30802/AALAS-CM-18-000030
   PubMed Web of Science ®Google Scholar
• Liu J, Li M, Song B, et al. Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft. Urol Oncol. 2013;31:264–270. doi:10.1016/j.urolonc.2011.01.003
   PubMed Web of Science ®Google Scholar
• Zhang X, Li F, Zheng Y, et al. Propofol reduced mammosphere formation of breast cancer stem cells via PD-L1/Nanog in vitro. Oxid Med Cell Longev. 2019;2019:9078209. doi:10.1155/2019/9078209
   PubMed Web of Science ®Google Scholar
• Klopp AH, Lacerda L, Gupta A, et al. Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One. 2010;5(8):e12180. doi:10.1371/journal.pone.0012180
   PubMed Web of Science ®Google Scholar
• Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991–4001. doi:10.1158/0008-5472.CAN-10-3175
   PubMed Web of Science ®Google Scholar
• Yao H-J, Zhang Y-G, Sun L, Liu Y. The effect of hyaluronic acid functionalize d carbon nanotubes loaded with salinomycin on gastric cancer stem cells. Biomaterials. 2014;35:9208–9223. doi:10.1016/j.biomaterials.2014.07.033
   PubMed Web of Science ®Google Scholar
• Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. Br Med J. 2005;530:1304–1305. doi:10.1136/bmj.38415.708634.F7
   Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–258. doi:10.2337/diacare.29.02.06.dc05-1558
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–1625. doi:10.2337/dc08-2175
   PubMed Web of Science ®Google Scholar
• Landman GW, Kleefstra N, van Hateren KJJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322–326. doi:10.2337/dc09-1380
   PubMed Web of Science ®Google Scholar
• Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F, Nicolucci A. Metformin therapy and risk of can- cer in patients with type 2 diabetes: systematic review. PLoS One. 2013;8:e71583. doi:10.1371/journal.pone.0071583
   PubMed Web of Science ®Google Scholar
• Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res. 2010;3:1451–1461. doi:10.1158/1940-6207.CAPR-10-0157
   PubMed Web of Science ®Google Scholar
• Miraglia S, Godfrey W, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90:5013–5021. doi:10.1182/blood.V90.12.5013
   PubMed Web of Science ®Google Scholar
• Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002–5012. doi:10.1182/blood.V90.12.5002
   PubMed Web of Science ®Google Scholar
• Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18:1127–1134. doi:10.1089/scd.2008.0338
   PubMed Web of Science ®Google Scholar
• Missol-Kolka E, Karbanova J, Janich P, et al. Prominin-1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate. Prostate. 2011;71:254–267. doi:10.1002/pros.21239
   PubMed Web of Science ®Google Scholar
• Zhou F, Teng F, Deng P, Meng N, Song Z, Feng R. Recent progress of nano-drug delivery system for liver cancer treatment. Anticancer Agents Med Chem. 2018;17(14):1884–1897. doi:10.2174/1871520617666170713151149
   PubMed Web of Science ®Google Scholar
• Huang P, Wang X, Liang X, et al. Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. Acta Biomater. 2019;85:1–26. doi:10.1016/j.actbio.2018.12.028
   PubMed Web of Science ®Google Scholar
• Fang Z, Pan S, Gao P, et al. Stimuli-responsive charge-reversal nano drug delivery system: the promising targeted carriers for tumor therapy. Int J Pharm. 2020;575:118841. doi:10.1016/j.ijpharm.2019.118841
   PubMed Web of Science ®Google Scholar
• Ashfaq UA, Riaz M, Yasmeen E, Yousaf MZ. Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Crit Rev Ther Drug Carrier Syst. 2017;34(4):317–353. doi:10.1615/CritRevTherDrugCarrierSyst.2017017845
   PubMed Web of Science ®Google Scholar
• Xue J, Li R, Gao D, Chen F, Xie H. CXCL12/CXCR4 axis-targeted dual-functional nano-drug delivery system against ovarian cancer. Int J Nanomedicine. 2020;15:5701–5718. doi:10.2147/IJN.S257527
   PubMed Web of Science ®Google Scholar
• Mi X, Hu M, Dong M, et al. Folic acid decorated zeolitic imidazolate framework (ZIF-8) loaded with baicalin as a nano-drug delivery system for breast cancer therapy. Int J Nanomedicine. 2021;16:8337–8352. doi:10.2147/IJN.S340764
   PubMed Web of Science ®Google Scholar
• Yang X, Chen S, Liu X, Yu M, Liu X. Drug delivery based on nanotechnology for target bone disease. Curr Drug Deliv. 2019;16(9):782–792. doi:10.2174/1567201816666190917123948
   PubMed Web of Science ®Google Scholar
• Mokhtarzadeh A, Hassanpour S, Vahid ZF, et al. Nano-delivery system targeting to cancer stem cell cluster of differentiation biomarkers. J Control Release. 2017;266:166–186. doi:10.1016/j.jconrel.2017.09.028
   PubMed Web of Science ®Google Scholar
• Liu B, Yang W, Che C, et al. Drug delivery system of AS1411 functionalized graphene oxide based composites. Chem Open. 2021;10(4):408–413. doi:10.1002/open.202000226
   Google Scholar
• Liu Y, Pu Y, Sun L, et al. Folic acid functionalized γ-Cyclodextrin C60, a novel vehicle for tumor-targeted drug delivery. J Biomed Nanotechnol. 2016;12:1393–1403. doi:10.1166/jbn.2016.2275
   PubMed Web of Science ®Google Scholar
• Wu HH, Zhou Y, Tabata Y, Gao JQ. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release. 2019;294:102–113. doi:10.1016/j.jconrel.2018.12.019
   PubMed Web of Science ®Google Scholar
• Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol Ther. 2021;226:107871. doi:10.1016/j.pharmthera.2021.107871
   PubMed Web of Science ®Google Scholar
• Yu H, Jin F, Liu D, et al. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury. Theranostics. 2020;10(5):2342–2357. doi:10.7150/thno.40395
   PubMed Web of Science ®Google Scholar